138 related articles for article (PubMed ID: 8209278)
1. Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
Palackdharry CS; Krigel RL
Semin Oncol; 1994 Jun; 21(3 Suppl 4):6-11. PubMed ID: 8209278
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
3. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Crawford J; George M
Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
5. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
7. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer.
Chang AY; Asbury RF; Boros L; Garrow GC; Hsieh S
Semin Oncol; 1995 Jun; 22(3 Suppl 7):9-12. PubMed ID: 7610399
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
Thongprasert S
J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
[TBL] [Abstract][Full Text] [Related]
15. Anticipated administration of GM-CSF in the treatment of non small cell lung cancer.
Erkisi M; Erkurt E; Zeren H; Tunali C; Kocabas A; Burgut R
J Exp Clin Cancer Res; 2001 Sep; 20(3):345-9. PubMed ID: 11718213
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.
Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
Semin Oncol; 1992 Dec; 19(6 Suppl 12):58-63. PubMed ID: 1336623
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
20. Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group Study (HeCOG).
Nicolaides C; Klouvas G; Fountzilas G; Athanassiadis A; Skarlos D; Samantas E; Kosmidis P; Mylonakis N; Pavlidis N
J Exp Clin Cancer Res; 1997 Mar; 16(1):91-4. PubMed ID: 9148868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]